Vertex doubles down on diabetes – acquires firm and resumes stem cell study
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14245684.ece/ALTERNATES/schema-16_9/20191023-212654-7-4929x2766ma.jpg)
US-based Vertex Pharmaceuticals, a biotech firm developing a stem cell-derived candidate for the treatment of type 1 diabetes, is set to acquire a privately owned firm focused on the same area, Viacyte, a company press release reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Vertex has initial success in new diabetes project
For subscribers
Diamyd Medical meets study goal with diabetes vaccine
For subscribers